Exercise's secret power on diabetes revealed in new study
NCT ID NCT04754581
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how exercise training changes the way muscles and fat tissue handle insulin in people with type 2 diabetes. About 39 adults aged 30-65 who are sedentary and have type 2 diabetes will take part. Researchers will use PET scans and small tissue samples to measure glucose uptake before and after an exercise program.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
39 people
The number who actually took part.
- Started
-
Mar 2021
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
30 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 30-65 years 2. Men and women 3. Body mass index (BMI) between 25 and 45 kg/m2 4. Sedentary (1 day or less per week of structured exercise) 5. Type 2 diabetes mellitus determined by self-report or by a fasting glucose \>126mg/dl 6. Weight stable (± 2 kg) for prior 3 months 7. Willing to commit to the schedule of assessment visits, including the exercise intervention Exclusion Criteria: 1. Currently taking insulin, injectable incretin mimetics and thiazolidinediones 2. Taking more than two glucose-lowering medications 3. Resting blood pressure ≥ 160/100 mm Hg 4. Triglycerides ≥ 500 mg/dL 5. Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the principal investigator would compromise participant safety or the participants' ability to complete the exercise training protocol 6. Any significant disease or unstable medical condition (i.e., coronary heart disease, chronic renal failure, chronic hepatic disease, severe pulmonary disease) 7. Presence of clinically significant abnormalities on electrocardiogram (ECG) that is a contra-indication to exercise training 8. Pulse check ("Allen test") indicates participant has poor blood flow in the hands 9. Cancer (active malignancy with or without concurrent chemotherapy; except for basal cell carcinoma) 10. Pregnancy during the previous 6 months, lactating, or planned pregnancy in the next year 11. Use of drugs known to affect energy metabolism or body weight: including, but not limited to orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc 12. Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures 13. Participant is currently taking anti-inflammatory medication or has had inflammatory medication within 1 week prior to screening (including over the counter formulations: e.g. Aleve, Motrin, Ibuprofen, Naproxen, low dose ASA. 14. New onset (\<3 months on a stable regime) hormone replacement therapy 15. Current use of beta-adrenergic blocking agents 16. Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months 17. Increased liver function tests (AST/ALT/GGT/or alkaline phosphatase greater than 2.5 times the upper limit of normal) 18. Abnormal blood count/anemia, blood transfusion or blood donation within the last 2 months 19. Current smokers (smoking within the past 3 months prior to screening visit, including any/all tobacco products) 20. Current drug or alcohol abuse/dependence 21. Metal implants (pace-maker, aneurysm clips) based on investigator's judgment at screening 22. Not physically capable of performing the exercise required of the study protocols 23. Plans to be away \>2 weeks in the next 3 months 24. Unable to participate in Magnetic Resonance Imaging (MRI) assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on investigator's judgment at screening. 25. Unable to tolerate MRI or claustrophobia. 26. Nickel allergy 27. Lidocaine allergy 28. Unable or unwilling to communicate with staff or to provide written informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AdventHealth Translational Research Institute
Orlando, Florida, 32804, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mindfulness and yoga rewire diabetes habits?
- Can a vegan diet delivered online help people with type 2 diabetes?
- Tiny horses, big lessons: can ponies help kids tame diabetes?
- Gut microbes in pregnancy and infancy: a window into lifelong health?
- A blood test at 50 could flag your risk of five diseases. can an app stop them?
- Chatbot coach takes aim at diabetes risk after pregnancy